Chemokines as Novel Therapeutic Targets for Inflammatory Bowel Disease

被引：86

作者：

Nishimura, Miyuki

Kuboi, Yoshikazu ^{[2
]}

Muramoto, Kenzo ^{[2
]}

Kawano, Tetsu

Imai, Toshio ^{[1
]}

机构：

[1] KAN Res Inst Inc, Kobe MI R&D Ctr, Chuo Ku, Kobe, Hyogo 6500047, Japan

[2] Eisai & Co Ltd, Innovat Biol Labs, Tsukuba, Ibaraki, Japan

来源：

CONTEMPORARY CHALLENGES IN AUTOIMMUNITY | 2009年 / 1173卷

关键词：

chemokines; chemokine receptors; inflammatory bowel disease; Crohn's disease; ulcerative colitis; INTRAEPITHELIAL LYMPHOCYTES; EPITHELIAL-CELLS; REGULATED PRODUCTION; INCREASED EXPRESSION; CROHNS-DISEASE; COLITIS; TRAFFICKING; MICE; FRACTALKINE; IMMUNITY;

D O I：

10.1111/j.1749-6632.2009.04738.x

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC) are illness characterized by a chronic clinical course of relapse and remission associated with self-destructive inflammation of the gastrointestinal tract. In both UC and CD, leukocyte infiltration into the intestine is fundamental event in disease development and progression where the chemokines and their receptors are orchestrating the tissue-specific and the cell type-selective trafficking of leukocytes. In this review, we will discuss the homeostatic and inflammatory roles of the chemokines and their receptors with their potentials and promise as molecular targets for therapeutic interventions in human IBD, focusing on the recently identified role of the CX3CL1-CX3CR1 axis, as well as the CCL20-CCR6, CCL25-CCR9, and CXCL10-CXCR3 pathways.

引用

页码：350 / 356

页数：7

共 50 条

[1] Novel therapeutic targets for inflammatory bowel disease
Argollo, Marjorie
Fiorino, Gionata
Hindryckx, Pieter
Peyrin-Biroulet, Laurent
Danese, Silvio
[J]. JOURNAL OF AUTOIMMUNITY, 2017, 85 : 103 - 116
[2] Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise
Trivedi, Palak J.
Adams, David H.
[J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S641 - S652
[3] Chemokines as novel therapeutic targets in inflammatory diseases
Ajuebor, MN
Swain, MG
Perretti, M
[J]. BIOCHEMICAL PHARMACOLOGY, 2002, 63 (07) : 1191 - 1196
[4] Therapeutic targets in inflammatory bowel disease
Fluxa, Daniela
Abreu, Maria T.
[J]. REVISTA MEDICA CLINICA LAS CONDES, 2019, 30 (04): : 315 - 322
[5] Therapeutic targets in inflammatory bowel disease
Di Sabatino, A.
[J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2022, 52
[6] Chemokines: therapeutic targets for autoimmune and inflammatory renal disease
Kelley, VR
Rovin, BH
[J]. SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 2003, 24 (04): : 411 - 421
[7] Chemokines: therapeutic targets for autoimmune and inflammatory renal disease
Vicki Rubin Kelley
Brad H. Rovin
[J]. Springer Seminars in Immunopathology, 2003, 24 : 411 - 421
[8] Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets
Yadav, Vipul
Varum, Felipe
Bravo, Roberto
Furrer, Esther
Bojic, Daniela
Basit, Abdul W.
[J]. TRANSLATIONAL RESEARCH, 2016, 176 : 38 - 68
[9] Hydroxylases as therapeutic targets in inflammatory bowel disease
Cummins, Eoin P.
Doherty, Glen A.
Taylor, Cormac T.
[J]. LABORATORY INVESTIGATION, 2013, 93 (04) : 378 - 383
[10] Novel Targets for Therapeutic Intervention in Inflammatory Bowel Disease: Research Drives Clinic
Argollo, Marjorie
Danese, Silvio
[J]. CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (01) : 5 - 6

← 1 2 3 4 5 →